A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

被引：0
|
作者：
Angelo Camporeale
David Kudrow
Ryan Sides
Shufang Wang
Annelies Van Dycke
Katherine J. Selzler
Virginia L. Stauffer
机构：
[1] Eli Lilly Italia,Neurology Department
[2] California Medical Clinic for Headache,undefined
[3] UCLA David Geffen School of Medicine,undefined
[4] Eli Lilly and Company Corporate Center,undefined
[5] AZ Sint-Jan Brugge,undefined
来源：
BMC Neurology | / 18卷
关键词：
Migraine; Headache; Galcanezumab; CGRP;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia
    Fumihiko Koiwa
    Yu Sato
    Meiko Ohara
    Kaoru Nakanishi
    Masafumi Fukagawa
    Tadao Akizawa
    [J]. Scientific Reports, 13
  • [22] Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia
    Koiwa, Fumihiko
    Sato, Yu
    Ohara, Meiko
    Nakanishi, Kaoru
    Fukagawa, Masafumi
    Akizawa, Tadao
    [J]. SCIENTIFIC REPORTS, 2023, 13 (01)
  • [23] Safety of long-term use of linezolid: results of an open-label study
    Vazquez, Jose A.
    Arnold, Anthony C.
    Swanson, Robert N.
    Biswas, Pinaki
    Bassetti, Matteo
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1347 - 1354
  • [24] An open-label study to evaluate the long-term safety of zelrix™, a sumatriptan iontophoretic patch for the treatment of acute migraine
    Smith, T.
    Pierce, M.
    Griesser, J.
    Sebree, T.
    O'Neill, C.
    [J]. CEPHALALGIA, 2011, 31 (01) : 120 - 120
  • [25] Long-Term, Open-Label Safety Study of Oral Almotriptan 12.5 mg for the Acute Treatment of Migraine in Adolescents
    Berenson, Frank
    Vasconcellos, Elza
    Pakalnis, Ann
    Mao, Lian
    Biondi, David M.
    Armstrong, Robert B.
    [J]. HEADACHE, 2010, 50 (05): : 795 - 807
  • [26] Safety of Rimegepant in Adults with Migraine and Cardiovascular Risk Factors: Analysis of a Multicenter, Long-Term, Open-Label Study
    True, David
    Mullin, Kathleen
    Croop, Robert
    [J]. PAIN AND THERAPY, 2024, 13 (05) : 1203 - 1218
  • [27] Long-Term Cardiovascular Safety of Lasmiditan for the Acute Treatment of Migraine for up to One Year: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)
    Rosen, N. L.
    Mathew, P. G.
    Buchanan, A. S.
    Baygani, S.
    Hochstetler, H.
    Khanna, R.
    [J]. HEADACHE, 2020, 60 : 111 - 111
  • [28] Shift from Chronic Migraine to Episodic Migraine Status in a Long-Term Phase 3 Study of Galcanezumab
    Hindiyeh, N. A.
    Detke, H. C.
    Day, K.
    Lipsius, S.
    Aurora, S. K.
    Diener, H.
    [J]. HEADACHE, 2019, 59 : 103 - 103
  • [29] A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine
    Croop, Robert
    Madonia, Jennifer
    Hould, Jennifer
    Mosher, Linda
    Lovegren, Meghan
    Lipton, Richard
    [J]. NEUROLOGY, 2023, 100 (17)
  • [30] LONG-TERM CARDIOVASCULAR SAFETY OF LASMIDITAN FOR THE ACUTE TREATMENT OF MIGRAINE FOR UP TO ONE YEAR: INTERIM RESULTS OF AN OPEN-LABEL PHASE 3 STUDY (GLADIATOR)
    Buchanan, Andrew
    Baygani, Simin K.
    Rosen, Noah
    Mathew, Paul G.
    Hochstetler, Helen
    Khanna, Rashna
    [J]. CEPHALALGIA, 2020, 40 : 49 - 50
12345